Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.67 USD
+0.06 (3.73%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXRX 1.67 +0.06(3.73%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Other News for LXRX
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Buy Rating Affirmed for Lexicon Pharmaceuticals on Promising INPEFA Heart Failure Treatment Data
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA? (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
Lexicon:INPEFA benefited heart failure patients regardless of diabetes duration
Biotech Alert: Searches spiking for these stocks today